Abbvie Net Revenue
Net Revenue of Abbvie 2008-2021
Amounts are in $millions.
| Year | Net Revenue ($mn) |
| 2021 | $56,197 |
| 2020 | $45,804 |
| 2019 | $33,266 |
| 2018 | $32,753 |
| 2017 | $28,216 |
| 2016 | $25,638 |
| 2015 | $22,859 |
| 2014 | $19,960 |
| 2013 | $18,790 |
| 2012 | $18,380 |
| 2011 | $17,444 |
| 2010 | $15,638 |
| 2009 | $14,214 |
| 2008 | $14,179 |
2021: In 2021, the net revenues of AbbVie grew to $56.2 billion compared to $45.8 billion in 2020.
Net Revenue of AbbVie in 2018 grew to $32.8 billion compared to $28.22 billion in 2017.
AbbVie is a global, research-based biopharmaceutical company. It develops and markets advanced therapies for some of the world’s most complex and serious diseases. Its products are made to treat conditions like chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, like Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; as well as other serious health conditions.